Dr. laura biganzoli continues to drive impactful research in breast cancer and geriatric oncology.
In September 2024, she co-authored a study in the New England Journal of Medicine showing that trastuzumab deruxtecan after endocrine therapy significantly improves progression-free survival in HER2-low metastatic breast cancer, offering a promising new treatment approach.
Beyond advancing targeted therapies, Dr. Biganzoli is advocating for greater inclusion of older patients in clinical trials. In October 2024, she published a review on barriers to including older patients in clinical trials, advocating for better trial design to improve cancer care for aging populations. Additionally, she contributed to a 2024 consensus project on standardized early breast cancer follow-up within public health systems.
Dr. Biganzoli’s work continues to advance both targeted therapies and patient-centered care, ensuring better treatment options for all patients.
Read more: https://lnkd.in/gDxPzUQa
